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We show that the clinical phenotype associated with BRD4 haploinsufficiency 31 
overlaps with Cornelia de Lange syndrome (CdLS) – most often caused by mutation of 32 
NIPBL.  More typical CdLS was observed with a de novo BRD4 missense variant, which 33 
retains the ability to co-immunoprecipitate with NIPBL but which binds poorly to 34 
acetylated histones. BRD4 and NIPBL display correlated binding at super-enhancers 35 
and appear to co-regulate developmental gene expression. (66 words)   36 
Super-enhancers are clustered cis-regulatory elements (CRE) controlling genes 37 
important for cell type specification.  Super-enhancers are molecularly defined as genomic 38 
intervals with high levels of H3K27 acetylation and binding of both BRD4 and the mediator 39 
complex1.  A critical role for cohesin in super-enhancer function has been recently reported 2.  40 
Acute depletion of cohesin resulted in disruption of higher-order chromatin structure and 41 
disordered transcription of genes predicted to be under super-enhancer control.   The most 42 
widely studied human cohesinopathy is Cornelia de Lange syndrome (CdLS), a severe 43 
multisystem neurodevelopmental disorder, which is associated with a generalized 44 
deregulation of developmental genes3,4. Typical CdLS is caused by heterozygous or mosaic 45 
loss-of-function (LOF) mutations in the gene encoding NIPBL. NIPBL is recruited to sites of 46 
double-strand breaks in DNA5 and functions as a transcriptional activator6 but it is best known 47 
for its role in loading the cohesin complex onto DNA and is required for cohesin-mediated 48 
loop extrusion and TAD formation7,8 9. Causative mutations in the genes encoding the core 49 
components of the cohesin ring (SMC1A, SMC3, RAD21)10–12 and the SMC3 deacetylase 50 
HDAC813 have been identified in CdLS-like conditions. However, individuals with de novo 51 
mutations in the chromatin associated/modifying proteins ANKRD1114,15, KMT2A4 and 52 
AFF416, which have no known association with cohesin can also present with CdLS-like 53 
disease.   54 
To identify novel disease loci we studied 92 individuals with CdLS in whom no 55 
plausibly diagnostic variants could be identified in the known causative genes.  In this group 56 
we identified 2/92 (2.2%) individuals with de novo mutations affecting BRD4. The first 57 
individual had a CdLS-like condition and a heterozygous 1.04 Mb deletion encompassing 58 
BRD4 (plus 28 other protein-coding genes (Family 4198; DECIPHER 281165)) (Fig. 1A, 59 
Supplemental Fig. 1&2). Targeted re-sequencing in the remaining 91 affected individuals 60 
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identified an individual, with more typical CdLS, who has a de novo missense mutation 61 
located in the second bromodomain (BD2) of BRD4 (3049; NM_058243.2  c.1289A>G, 62 
p.(Tyr430Cys))(Fig. 1B, Supplemental Fig. 5). Subsequently two affected individuals who 63 
were not part of the original cohort were identified with de novo frame-shift mutations in 64 
BRD4.  The first of these was identified via ongoing screening of individuals with CdLS-like 65 
disorders (CDL038 NM_058243.2 c.1224delinsCA p.(Glu408Aspfs*4) ; Fig. 1B).  The second 66 
indel variant was discovered through analysis of trio whole exome sequencing data generated 67 
by the Deciphering Developmental Disorders study 17 (DDD; DECIPHER 264293 68 
NM_058243.2 c.691del p.(Asp231Thrfs*9); Fig. 1B).  The latter individual was recruited to 69 
DDD on the basis of intellectual disability, mild short stature and a ventricular septal defect 70 
but had not been suspected to have CdLS (Supplemental Table 1). On review of 7 reported 71 
heterozygous multigenic deletions encompassing BRD4 we found a significant phenotypic 72 
overlap with CdLS (Supplemental Fig. 3; Supplemental Table 1) with at least 2/7 fulfilling 73 
the established CdLS diagnostic criteria18. Taken together; these data support BRD4 74 
haploinsufficiency as the likely genetic mechanism for the CdLS-like phenotype.   75 
It has been previously reported that mice carrying heterozygous LOF mutations in 76 
Brd4 show marked early postnatal mortality, severe prenatal onset growth failure, 77 
abnormalities of the craniofacial skeleton and reduced body fat19; all features common in 78 
CdLS.  Brd4 homozygous null embryos die soon after implantation. Heterozygous LOF 79 
mutations in only 12 other non-imprinted autosomal mouse genes have both postnatal 80 
lethality and postnatal growth retardation recorded as features in the Mouse Genome 81 
Informatics database (MGI); one of these being Nipbl 20 (Supplemental Fig. 4A-C). 4 of 82 
these 13 haploinsufficient mouse genes have been implicated in super-enhancer function 83 
(Brd4, Nipbl, Chd7 and Crebbp)1,21 (Supplemental Fig. 4E).   84 
BRD4, is a member of the bromodomain and extraterminal domain (BET) protein 85 
family with tandem bromodomains that ‘read’ acetylated lysine marks on chromatin. BRD4 86 
binds mostly to hyper-acetylated genomic regions that encompass promoters and enhancers 87 
and BRD4 levels are particularly high at super-enhancers22. BRD4 regulates transcription 88 
elongation by paused RNA polymerase II (Pol II) via mediating the release of Cdk9 activity, 89 
which results in phosphorylation of serine 2 of Pol II C-terminal domain (CTD). Tyr430, the 90 
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residue substituted in individual 3049 with the more typical CdLS phenotype (Fig. 1B), lies 91 
within the third alpha helix (αB) of the second bromodomain (BD2) of BRD4; close to the 92 
recognition site that mediates binding to acetylated lysine23. p.Tyr430Cys (Y430C) is a non-93 
conservative amino acid substitution which could plausibly impair the binding of BRD4 to 94 
acetyl lysine. Indeed, compared to wild-type BD1 and BD2, a tagged BRD4 BD2 containing 95 
the Y430C mutation shows reduced binding to acetylated histone peptides in vitro (Fig. 2A).  96 
In mouse BRD4 the “human equivalent” missense variant would be p.Tyr431Cys; the 97 
difference in amino acid numbering is the result of an “extra” proline in the poly-proline repeat 98 
(position 215-217 in the human protein; Supplemental Fig. 6).  To avoid confusion we will 99 
use Brd4Y430C as the mouse variant designation; we introduced this variant onto both alleles 100 
(Brd4Y430C/Y430C) of mouse embryonic stem cell (mESC) lines by Cas9-induced homology 101 
directed repair (HDR). BRD4 immuno-precipitation (IP) in Brd4Y430C/Y430C mESC shows 102 
impaired binding to acetylated histones (H3K9ac and K3K27ac) (Fig. 2B, Supplemental Fig. 103 
18).  104 
Label-free quantitative (LFQ) mass spectrometry (MS) following IP was performed 105 
using two different BRD4 antibodies on lysates from Brd4Y430C/Y430C and wild-type mESCs 106 
(Supplemental Table 4).  This detected 1,082 proteins present in BRD4 IP from both cell 107 
lines, 90 of which were absent in all IgG controls (Fig. 2C). Of these, BRD4 was the top hit 108 
with three of the remaining 89 proteins being NIPBL, Rad21 (core cohesin ring component) 109 
and Esco2 (SMC3 acetylase) (Fig. 2D, Supplemental Fig. 7). Other subunits of cohesin 110 
(SMC1A, SMC3, STAG2, PDS5A, PDS5B) also showed evidence of enrichment 111 
(Supplemental Fig. 8). The association of BRD4 with NIPBL was replicated using LFQ MS 112 
on an independent Brd4Y430C/Y430C mESC line created using the same genome editing 113 
protocol.  Reciprocal IPs using antibodies to NIPBL and SMC3 confirmed the BRD4 114 
interaction with both NIPBL and the core cohesin ring (Fig. 2E, Supplemental Fig. 9&20). In 115 
mESC Brd4Y430C/Y430C shows a similar level of NIPBL association to wild-type Brd4, 116 
suggesting that this interaction is unlikely to be mediated via co-binding to acetylated 117 
chromatin (Fig. 2E, Supplemental Fig. 19). 118 
In order to further assess the functional consequences of the BRD4 missense variant 119 
we generated F0 mouse embryos following zygote injections of reagents to induce Cas9-120 
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mediated HDR.  As judged from digital sectioning from optical projection tomography, the 121 
morphology of Brd4Y430C/+ and Brd4Y430C/Y430C F0 mouse embryos is indistinguishable from 122 
wild-type embryos.  We also generated apparently non-mosaic F0 embryos homozygous for a 123 
15bp in-frame deletion (NM_020508.4 c.1288_1302del; p.(Cys430_Asn434del; 124 
Supplemental Fig. 10); designated as Brd4C429_N433del/ C429_N433del to maintain consistency with 125 
human nomenclature) showing significant growth restriction at 13.5 dpc as their only obvious 126 
phenotype (Supplemental Fig. 11).  We derived mouse embryonic fibroblasts (MEF) from 127 
13.5 dpc F0 Brd4Y430C/Y430C, Brd4C429_N433del/ C429_N433del and control mouse embryos. The MEFs 128 
lines initially established from Brd4C429_N433del/ C429_N433del embryos did not survive in long-term 129 
culture, but we were able to generate sufficient cells for western blot analysis. Both wild-type 130 
and Brd4Y430C/Y430C MEF lines expressed comparable levels of BRD4 protein.  However, in 131 
Brd4C429_N433del/ C429_N433del MEFs the BRD4 band was undetectable (Supplemental Fig. 12) 132 
using an antibody raised against a peptide representing amino acid numbers 1312-1362 in 133 
the mature peptide.  The apparent null status of these cells may be the result of rapid 134 
degradation of the abnormal protein or an artifact due to change in the epitope.  The latter 135 
may also explain the survival of these homozygous embryos past implantation.  136 
BRD4 Chromatin IP (ChIP) from Brd4Y430C/Y430C MEF showed reduced binding to the 137 
promoters and super-enhancers of known BRD4 targets compared with wild-type MEF 138 
(Figure 2F). To assess regions of common binding, we performed BRD4 ChIP-seq on wild-139 
type mESC and compared this to publicly accessible NIPBL and BRD4 ChIP-seq data from 140 
mouse (Supplemental Fig. 13) and human (Supplemental Fig. 14) ESCs.  We used the 141 
intersection of the BRD4-bound and NIPBL-bound genomic intervals from the ChIP-seq data 142 
to create a set of high-confidence shared binding sites.  By comparing different functional 143 
genomic categories, mESC super-enhancers show the highest level of enrichment with 144 
heterochromatin being the least enriched (Figure 2G&H, Supplemental Fig.15).  To look for 145 
any common functional effect on gene expression we then generated array-based 146 
transcriptome data from control, Brd4Y430C/Y430C and Nipbl+/- MEFs (Supplemental Fig. 16). Of 147 
the >18000 genes probed on the microarray, 3049 have a transcription start site within 1Mb of 148 
a defined MEF super-enhancer (Super Enhancer Archive).  These super-enhancer-149 
associated genes showed significantly higher level of differential expression in both Brd4 (p = 150 
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0.002) and Nipbl (p = 0.006) mutant cells compared to genes that are not super-enhancer 151 
associated. There is also a significant overlap in the specific genes that show differential 152 
expression in both BRD4 and NIPBL mutant MEFs (Supplemental Fig. 17).   153 
CdLS can be considered a transcriptomopathy4, presumed to result from loss of 154 
cohesin-dependent chromatin loops or a cohesin-independent NIPBL-mediated 155 
transcriptional activity6. Our identification of de novo heterozygous loss of function mutations 156 
in BRD4 in a CdLS-like disorder, together with the functional genomic data presented above, 157 
suggests that CdLS may be more specifically defined as a disorder of super-enhancer 158 
function.  Delineation of any direct or indirect physical interaction and/or functional co-159 
dependency of BRD4 with NIPBL can now reasonably become a topic of investigation. 160 
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Figure	Legends:	202 
Figure 1. BRD4 mutations in CdLS and CdLS-like disorders. A. Pedigree drawing of 203 
proband with CdLS-like disorder associated with a de novo 1.04 Mb microdeletion of 19p (red 204 
bar), the location of which is shown on the Log2 ratio plot of the array-based comparative 205 
genomic hybridization. Below on the left is a key to the symbols using in the pedigree images.  206 
To the right of this is the RefSeq gene content of the deleted region with the location of BRD4 207 
indicated in orange.  The genes colored green are known disease genes associated with 208 
phenotypes that are not consistent with the clinical presentation in this case. Details of each 209 
is given in the supplementary notes.  B. Pedigree drawings and facial photographs of 210 
probands with intragenic mutations of BRD4, with cartoon of BRD4 protein indicating the 211 
position of each of the variants in relation to the first bromodomain (BD1), the second 212 
bromodomain (BD2) and the N-terminal extra terminal domain (NET). The position of an 213 
inherited p.His304Tyr variant (orange text) reported in a single family with inherited cataracts 214 
is indicated and discussed in supplementary notes.  215 
 216 
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Figure 2. Binding of BRD4 wild-type and BRD4 p.Tyr430Cys variant to histone and non-218 
histone proteins. A. Specificity of binding to acetylated histone tail peptides of wild-type 219 
BRD4 Bromodomain 1 (BRD4 BD1 WT), wild-type BRD4 Bromodomain 2 (BRD4 BD2 WT), 220 
and BRD4 p.Tyr430Cys mutant BD2 (BRD4 BD2 Y430C). B. Cropped immunoblots of 221 
endogenous BRD4 IPs and rabbit normal IgG (control) from Brd4 wild-type and Brd4Y430C/Y430C 222 
mESCs. Input =1% of mESC nuclear extract. Antibodies detect BRD4, H3K9ac, H3K27ac, 223 
H4K8ac and H3. C. Heatmap of the label-free mass spectrometry quantitative output values 224 
(average of triplicates) assigned to each protein following IP from BRD4 wild-type (WT) and 225 
BRD4-Y430C (MUT) mESC using IgG only control or Abcam/Bethyl antibody against BRD4. 226 
D.  A plot of the log Andromeda scores assigned to the 90 proteins which are absent in the 227 
IgG controls and present in both cell lines using both BRD4 antibodies. Horizontal scatter aids 228 
visibility of each open circle and has no data correlate. E. Cropped immunoblot of reciprocal 229 
IP using BRD4 and NIPBL antibodies in Brd4 wild-type and Brd4Y430C/Y430C mESCs. 230 
Antibodies detect BRD4, NIPBL and SOX2. F. Percentage (%) input bound for BRD4 ChIP-231 
qPCR across genomic regions in WT and BRD4 Y430C mutant MEFs (error bars = standard 232 
error of the mean from n=2 biological replicates). G. Forest plot of the log2 odds ratio with 233 
confidence intervals (CI) of different functional genomic categories within intersecting regions 234 
from BRD4 and NIPBL mESC ChIP. H. UCSC Genome Browser graphic showing 235 
colocalisation of BRD4 and NIPBL ChIPseq peaks over the super enhancer (blue bar) at Klf4 236 
locus. H3K27ac, H3K4me1, H3K122ac and super enhancer tracks are previously published.  237 
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Online	Methods	Section	295 
Methods 296 
Patient ascertainment 297 
All the clinical research activity relating to this report has been in accordance with World 298 
Medical Association Declaration Of Helsinki on the Ethical Principles For Medical Research 299 
Involving Human Subjects.  The research was conducted using protocols approved by UK 300 
multicenter ethics committees under the references; 04:MRE00/19 (MRC HGU) and 301 
10/H0305/83 (DDD). Two of the affected individuals (4198 II:1 & 3049 II:1 Figure 1) are part 302 
of a larger cohort of patients with a diagnosis of CdLS or possible CdLS, referred by 303 
experienced clinical geneticists or pediatricians to the MRC Human Genetics Unit for 304 
research genetic analysis12. The third (CDL038) was referred to the DNA Diagnostic 305 
Laboratory in NHS Lothian with a CdLS-like disorder. The final affected individual (264293) 306 
was identified using the trio whole exome sequence data generated by the Deciphering 307 
Developmental Disorders study. 308 
 309 
Array comparative genomic hybridization 310 
Array comparative genomic hybridization (aCGH) was performed using the Nimblegen 135k 311 
microarray platform (Roche Nimblegen) as described previously21. Results were compared 312 
with the Database of Genomic Variants and polymorphic CNVs excluded.    313 
 314 
Droplet digital PCR 315 
A pair of oligonucleotide primers and the matching 5′ FAM-labelled Universal Probe Library 316 
(UPL) probe (# 25) (Roche) were designed to target coding exon 17 of the BRD4 gene using 317 
ProbeFinder software version 2.50 (Roche).        318 
Each 20 µl ddPCR reaction consisted of 40 ng of genomic DNA, 1X ddPCR SuperMix for 319 
probes (No dUTP) (Bio-Rad Inc.), forward and reverse primers at 1 µM each, UPL probe #25 320 
at 250 nM, and 1X 5′ VIC-labelled RNase P TaqMan Copy Number Reference assay (Thermo 321 
Fisher Scientific). Droplet generation using the QX200 droplet generator (Bio-Rad Inc.) 322 
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followed by amplification, 95oC for 10 minutes, 40 cycles of 94oC for 30 seconds and 57oC for 323 
60 seconds, and a final incubation at 95oC for 10 minutes, were performed as per 324 
manufacturer’s instructions (Bio-Rad Inc.). Following completion of the PCR, plates were read 325 
using the QX200 droplet reader (Bio-Rad Inc.). Analysis of droplet counts, amplitudes and 326 
DNA copy number were performed with QuantaSoft software (Bio-Rad Inc.) for channel 1 = 327 
FAM and channel 2 = VIC.       328 
 329 
Mutation analysis by DDD Trio Exome Sequencing, Ion AmpliSeq PCR-Ion PGM, and 330 
Sanger sequencing  331 
As part of a DDD Complementary Analysis Protocol #35 VCF files on the first 4293 trios with 332 
whole exome sequence were searched for candidate de novo mutations in BRD4.  Only one 333 
possible de novo disruptive variant was identified in BRD4. This variant was validated as de 334 
novo using the approach mentioned below. No other plausible cause for the developmental 335 
disorder was apparent on trio based whole exome analysis.   336 
An AmpliSeq panel encompassing the coding exons of BRD4 and nine other candidate genes 337 
was designed using the Ion AmpliSeq Designer tool (Life Technologies, IAD41056). Library 338 
preparation and sequencing on the Ion PGM platform (Life Technologies), followed by 339 
sequence alignment and variant calling on software NextGENe version 2.3.3 (Soft Genetics) 340 
were performed as described previously12. A total of 92 individuals were screened, who had 341 
previously scored as negative for mutations in NIPBL, SMC1A, SMC3, HDAC8 and RAD21, 342 
and large-scale genomic deletions/duplications.  The same panel also applied to subsequent 343 
clinical referrals to the NHS DNA diagnostic laboratory in Edinburgh was used to identify one 344 
further de novo heterozygous loss of function mutation in an individual who had a CdLS-like 345 
phenotype. 346 
Any significant variants were confirmed by Sanger sequencing and analysed using Mutation 347 
Surveyor software version 3.30, as described previously21. The BRD4 sequence identifier, 348 
NC_000019.10 was used in the analysis. Sequence variant nomenclature is reported 349 
according to the BRD4 transcript variant, NM_058243. Primer sequences and PCR conditions 350 
are available upon request.  351 
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 352 
Plasmids, expression and purification of proteins 353 
Human BRD4 BD1 and BD2 plasmids were kindly gifted by Prof Stefan Knapp (Nuffield 354 
Department of Clinical Medicine, Oxford). Proteins were expressed and purified at the 355 
Edinburgh Protein Production Facility (EPPF) as described previously22. 356 
Site-directed Mutagenesis 357 
The point mutation c.1289A>G, predicted to result in the protein variant p.Tyr430Cys (Y430C) 358 
was introduced into the BRD4-BD2 and FLAG-mBRD4 constructs using the QuikChange II 359 
XL Site-directed Mutagenesis kit (Agilent Technologies) following the manufacturer's 360 
instructions. The presence of the desired mutations was confirmed by Sanger sequencing. 361 
CRISPR/Cas9 construct design 362 
Guide RNA (gRNAs) 1 and 2 were designed across p.Tyr430 using online tool DNA 2.0. The 363 
wild-type and mutant repair templates (chr17:32,220,150-32,220,271; GRCm38) were 364 
synthesized by IDT as 122 bp UltramerssODN bearing the desired sequence change. For 365 
genome editing in mouse embryonic stem cells (mESCs) gRNAs 1 and 2 were cloned into 366 
PX461 (Addgene plasmid #48140) and PX462 (Addgene plasmid #62987) respectively.  For 367 
genome editing in mouse embryos both gRNAs were cloned into PX461 and the full gRNA 368 
template sequence was amplified from the resulting PX461 clone using universal reverse 369 
primer and T7 tagged forward primers. The gRNA PCR template was used for in vitro RNA 370 
synthesis using T7 RNA polymerase (NEB), and the RNA template subsequently purified 371 
using RNeasy mini kit (Qiagen) purification columns. Cas9n mRNA was procured from Tebu 372 
Bioscience. 373 
Genome editing in mouse embryonic stem cells (mESCs) 374 
To generate mESCs carrying the p.Tyr430Cys missense variant in BRD4, 46C cells were 375 
cotransfected with gRNAs 1 and 2 (0.5 µg/ml) and the mutant repair template (0.5µg/2ml) 376 
using Lipofectamine® 3000 Transfection Reagent (ThermoFisher) as per the manufacturer’s 377 
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instructions. After 48 hours, successfully transfected cells were selected for: firstly by 378 
puromycin treatment, and subsequently by FACS based on GFP expression. Resulting GFP 379 
and puromycin positive cells were plated at 500 cells/10cm2. After 1 week, colonies were 380 
picked and plated in duplicate as 1 colony/well of a 96 well plate. Genomic DNA was 381 
extracted from the colonies and sequenced by Sanger sequencing. Wild-type clones and 382 
clones homozygous for the p.Tyr430Cys variant were expanded and frozen for later use.   383 
Genome editing in mouse embryos and generation of mouse embryonic fibroblast 384 
(MEFs) 385 
To generate mouse embryos carrying the p.Tyr430Cys variant in BRD4, injections were 386 
performed in single cell mouse zygotes. Injection mix contained Cas9 mRNA (50 ng/µl), 387 
gRNAs 1 and 2 (25 ng/µl) and each repair template DNA (75 ng/µl). The embryos were later 388 
harvested for analysis at 13.5 dpc stage of embryonic development. MEFs were isolated from 389 
limbs of individual E13.5 embryos by mincing in 1 ml of medium (DMEM, 10% FCS, 50 U/ml 390 
penicillin and 50 mg/ml streptomycin,). Resulting suspensions were grown at 37oC, 5% CO2 391 
and 3% O2, and non-adherent cells removed after 24 hours. MEFs from embryos with 392 
unedited Brd4 alleles, clean homozygous knock-in for p.Tyr430Cys in Brd4 393 
(Brd4Tyr430Cys/Tyr430Cys and homozygous knock-in for an in-frame deletion 394 
(Brd4Cys430_Asn434del/Cys430_Asn434del) alleles were used for further experimentation. 395 
 396 
Generation of heterozygous loss-of-function Nipbl MEFs: 397 
Mice with Nipbl floxed allele (a kind gift from Heiko Peters, University of Newcastle) were 398 
crossed with Cre745 mice (a kind gift from DJ Kleinjan, University of Edinburgh), containing a 399 
CAGGS-Cre construct in which Cre recombinase is under control of a chicken b-actin 400 
promoter to excise Nipbl exon 1. Embryos were collected at 13.5 dpc. MEFs were isolated 401 
from heterozygous Nipbl knockout embryo limbs by mincing in 1 ml of medium (DMEM, 10% 402 
FCS, 50 U/ml penicillin and 50 mg/ml streptomycin,). Resulting suspensions were grown at 403 
37oC, 5% CO2 and 3% O2, and non-adherent cells removed after 24 hours. 404 
 405 
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Histone tail peptide arrays  406 
A modified histone peptide array (Active motif, #13005) experiment was performed as 407 
described previously23. Briefly, the array was blocked in TBST buffer (10 mM Tris/HCl pH 8.3, 408 
0.05% Tween-20, 150 mM NaCl) containing 5% non-fat dried milk at 4°C overnight. The 409 
membrane was washed with TBST for 5 min, and incubated with 10 ηM purified His-tagged 410 
BRD4 BD1 or wild-type (WT) and p.Tyr430Cys (Y430C) BD2 domains, at room temperature 411 
(RT) for 1 hour in interaction buffer (100 mM (0.5 µg/3 ml) KCl, 20 mM HEPES pH 7.5, 1 mM 412 
EDTA, 0.1 mM DTT, 10% glycerol). After washing in TBST, the membrane was incubated 413 
with mouse α-His (Sigma, H1029, 1:2,000 dilution in TBST) for 1 hour at RT. The membrane 414 
was then washed 3 times with TBST for 10 min each at RT, and incubated with horseradish 415 
peroxidase conjugated α-mouse antibody (1:10,000 in TBST) for 1 hour at RT. The 416 
membrane was submerged in ECL developing solution (Pierce, #32209), imaged (Image-417 
quant, GE Healthcare) and the data quantified using array analyzer software (Active motif). 418 
 419 
Nuclear extract co-immunoprecipitation  420 
30 x 106  wild-type and p.Tyr430Cys (Y430C) BRD4 mESCs were trypsinised, pelleted and 421 
resuspended in 5 ml ice-cold swelling buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl2, 10 mM 422 
KCl, 0.5mM DTT, Complete Mini EDTA-free protease inhibitor (Roche)) for 5 minutes on ice. 423 
Nuclei were pelleted by centrifugation at 2,000 rpm for 5 minutes at 4°C. The resulting 424 
nuclear pellets were sonicated in 2 ml RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 1% 425 
NP-40, 0.5% sodium deoxycholate, benzonase and Complete Mini EDTA-free protease 426 
inhibitor (Roche)), using a Bioruptor® Plus sonication device (Diagenode) at 4°C, 30 seconds 427 
on, 30 seconds off. It was noted that prolonged (1 hour) exposure to the detergents in RIPA 428 
buffer affected the interactions of BRD4 as measured by mass spectrometry. Nuclear extracts 429 
were cleared by centrifugation at 13,000 rpm for 10 minutes at 4°C. Protein A Dynabeads (life 430 
technologies) were blocked prior to antibody coupling by washing 3 times with 5% BSA in 431 
PBS. Antibodies were coupled to the beads at 5 mg/ml by rotation for 1 hour at 4°C. 432 
Equivalent nuclear protein amounts were incubated with antibody coupled beads for 1 hour at 433 
4°C. Beads were washed and pulled down proteins analysed by mass spectrometry or 434 
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western blot. Antibodies used: BRD4 (Bethyl A301-985A100), SMC3 (Bethyl 0300-060A), 435 
NIPBL (Bethyl A301-779A) and normal rabbit IgG (Santa-Cruz, sc-2027).  436 
 437 
Western blots  438 
For western blot analysis beads were washed 5 times with RIPA buffer, bound proteins eluted 439 
by boiling in 1X NuPage LDS buffer (ThermoFisher Scientific) with 1X NuPage reducing 440 
agent (ThermoFisher Scientific) for 5 minutes and separated on a 3-8% tris-acetate gel 441 
(reciprocal BRD4/SMC3/NIPBL IPs and MEF cell lysates) or 4-12% bis-tris gel (BRD4 IPs for 442 
acetylated histone binding) (ThermoFisher Scientific). Following electrophoresis, proteins 443 
were transferred to nitrocellulose membranes (ThermoFisher Scientific) using iBlot 2 Dry 444 
Blotting System (ThermoFisher Scientific) for 7 minutes (when probing for proteins <250 kDa 445 
only) or to PVDF membranes by wet transfer for 90 minutes (when probing for proteins >250 446 
kDa) and incubated with primary antibodies overnight at 4°C. Membranes were washed 3 447 
times in TBST and probed with HRP-conjugated secondary antibody (anti-Rb/anti-goat, 448 
1:10,000) for 1 hour at RT. After 3 more washes in TBST, membranes were incubated with 449 
Pierce™ ECL Western Blotting Substrate (ThermoFisher Scientif ic) for 5 450 
minutes and imaged using (Image-quant, GE Healthcare). Antibodies used: BRD4 451 
(Bethyl A301-985A100, 1:3,000), SMC3 (Bethyl 0300-060A, 1:1,000), H3K27ac (Genetex 452 
GTX128944, 1:1,000), H4K8ac (Abcam ab15823, 1:1,000), H3K9ac (Abcam, ab10812, 453 
1:500), H3 (Abcam, ab1791, 1:5,000), NIPBL (Bethyl A301-779A, 1:1000),  SOX2 (Abcam 454 
ab97959, 1:1000)  Actin-b (Abcam ab8229, 1:500). 455 
 456 
Mass spectrometry 457 
For analysis by mass spectrometry, beads were washed 3 times with Tris-saline buffer, and 458 
excess buffer removed. Immunoprecipitations were digested on beads, desalted and 459 
analysed on a Q-Exactive plus mass spectrometer as previously described24. Proteins were 460 
identified and quantified by MaxLFQ25 by searching with the MaxQuant version 1.5 against 461 
the Mouse proteome data base (Uniprot). Modifications included C Carbamlylation (fixed) and 462 
M oxidation (variable). Bioinformatic analysis was performed with the Perseus software suite. 463 
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 464 
Chromatin immunoprecipitation-quantitative PCR 465 
Primary MEFs isolated from 13.5 dpc embryos were cultured for 3-4 passages in DMEM 466 
media supplemented with 15% FCS, 1% Pen/Strep, L-Glutamine, non-essential amino acids 467 
and Sodium pyruvate. Cells were harvested by trypsinizing and fixed immediately with 1% 468 
formaldehyde (Thermo Fisher Cat. 28906) (25°C, 10 min) in PBS, and stopped with 0.125 M 469 
Glycine. Chromatin immunoprecipitation (ChIP) was performed as described previously26. 470 
Briefly, cross linked cells were re-suspended in Farnham lysis buffer (5 mM PIPES pH 8.0, 85 471 
mM KCl, 0.5% NP-40, Complete Mini EDTA-free protease inhibitor (Roche)) for 30 minutes 472 
and centrifuged at 228 g for 5 minutes at 4°C. Nuclei were resuspended in RIPA buffer (1X 473 
PBS,  1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS (filtered 0.2 -0.45 micron filter unit) + 474 
Complete Mini EDTA-free protease inhibitor (Roche)) and sonicated using a Bioruptor® Plus 475 
sonication device (Diagenode) at full power for 40 minutes (30 seconds on, 30 seconds off) to 476 
produce fragments of 100-500 bp. 3 µg of each antibody was incubated with Protein A 477 
Dynabeads (ThermoFisher Scientific, 10001D) in 5 mg/ml BSA in PBS on a rotating platform 478 
at 4°C for two hours. An arbitrary concentration of 50 µg chromatin was incubated with 479 
antibody bound Dynabeads in a rotating platform at 4°C for 16 hours. Beads were washed 5 480 
times (5 minutes each) on a rotating platform with cold LiCl wash buffer (100 mM Tris pH 7.5, 481 
500 mM LiCl, 1% NP-40, 1% Sodium deoxycholate) and one time with RT TE buffer. ChIP 482 
complexes were eluted with elution buffer (1% SDS, 0.1 M NaHCO3) and Input and ChIP 483 
samples were incubated at 65°C for 5 hours to reverse the crosslinks. 2 µl of RNase A (20 484 
mg/ml) was added and samples were incubated at 37°C for 1 hour before 2 µl of Proteinase K 485 
was added and samples were incubated for 2 hours at 55°C. DNA was purified using 486 
QIAquick PCR Purification Kit (Qiagen, Cat. 28104), and analysed by qPCR for primers 487 
described in Supplementary Table 2. Antibodies used: rabbit IgG (Santa Cruz sc-2025), 488 
BRD4 (Bethyl A301-985A100). 489 
Chromatin immunoprecipitation-sequencing (ChIP-Seq) 490 
Wild-type mESCs were cultured in GMEM media supplemented with 10% FCS, 1% 491 
Pen/strep, L-glutamine, non-essential amino acids, sodium pyruvate and 1,000 U/ml 492 
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LIF. Cells were harvested by trypsinizing and fixed immediately with 1% formaldehyde 493 
(Thermo Fisher Cat. 28906) (25°C, 10 minutes) in PBS. This reaction was quenched with 494 
0.125 M Glycine. ChIP was carried out as above. After purification, DNA was eluted in 20 µl 495 
and libraries were prepared for ChIP and input samples as previously described27. Samples 496 
were sequenced at BGI (Hong Kong; 50-base single-end reads) using the HiSeq 4000 497 
system (Illumina).  498 
 499 
Transcriptome analysis  500 
RNA was extracted from Brd4Tyr430Cys/Tyr430Cys and Nipbl heterozygous null MEFs using the 501 
RNeasy Mini Kit (Qiagen) as per the manufacturer’s instructions. 1 µg of RNA was hybridised 502 
to a SurePrint G3 Mouse GE 8x60K microarray (Agilent; G4852A) and scanned on a 503 
Nimblegen scanner as described previously28.  504 
Quantile normalisation and background correction (method normexp) of the microarray data 505 
was carried out using the bioconductor package limma29. Gene level expression was 506 
calculated by averaging the probes signal that mapped to the same gene (Gene Symbols 507 
mapped to Probe identifiers obtained from GEO, GPL13912,  Agilent-028005 SurePrint G3 508 
Mouse GE 8x60K Microarray). The normalised signal for technical replicate samples was 509 
averaged prior to Differential expression (DE) analysis. 510 
 511 
Transcriptome analysis statistics 512 
Gene level differential expression was conducted using the bioconductor package limma29. 513 
Briefly, a linear model was fitted to each gene. Then empirical Bayes moderation was applied 514 
to the linear model fit to compute moderated t-statistics, moderated F statistic, and log-odds 515 
of differential expression. The Benjamini & Hochberg method was used to correct the p-516 
values for multiple testing. Genes were identified as significantly differentially expressed if the 517 
FDR q value < 0.1.  518 
To test whether genes (n= 3049/19113) with a transcription start site within 1Mb of MEF 519 
Super Enhancers (SE) are more highly ranked relative to other expressed genes in terms 520 
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differential expression  (t-statistic) we performed a Mean-rank Gene Set Test (geneSetTest, 521 
bioconductor package limma).  522 
 523 
A hypergeometric test was performed on the differentially expressed gene sets for Brd4 and 524 
Nipbl to determine if DE genes were significantly enriched between the two groups. 525 
 526 
ChIP-seq analysis  527 
Bowtie 2 (version 2.2.6) was used to map reads to mouse (mm9) and human (hg19) 528 
genomes (options bowtie2-align-s --wrapper basic-0)30. To calculate the correlation of NIPBL 529 
and BRD4 with other histone modifications (see Supplementary Table 3), the correlation of 530 
the ChIP-seq binding profiles across the genome was calculated. DeepTools (version 2.3.5) 531 
multiBamSummary was used to calculate the coverage of mapped reads in 150 bp sequential 532 
bins across the mm9/hg19 genome (options --binSize 150bp, --ignoreDuplicates,--black, 533 
ListFileName,--extendReads 150,–mappingquality 30)31. Genomic bins within Blacklisted 534 
regions and chrX and chrY were excluded from the analysis. Genomic bins were also 535 
restricted to regions of open chromatin using DNase I hypersensitive sites identified by the 536 
ENCODE project32 (see Supplementary Table 3).  537 
The genome wide coverage matrix was imported into R and Pearson's R was calculated. 538 
Correlation scores were visualised as a heatmap using the R package pheatmap (options; 539 
euclidean distance and complete clustering method) 33. 540 
 541 
Peak calling 542 
To call BRD4 and NIPBL bound regions we used the MACS peak caller (2.1.1). For BRD4 543 
peaks we used the parameters broadPeaks and an FDR cut-off of 0.1.  544 
For NIPBL we used the public ChIP-Seq dataset NIPBL in V6.5 (C57BL/6-129) murine ES 545 
cells (GEO ID, GSM560350) and, the accompanying whole cell extract dataset (GEO ID, 546 
GSM56035) as background.   547 
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For peak calling we used MACS with the parameters narrowPeaks and an FDR cut off of 0.1. 548 
To perform intersections on genomic ranges, such as peaks regions, we used bedtools 549 
intersect (2.26.0)34. 550 
 551 
Any peaks that intersected with the mm9 genome blacklist regions or mapped to non-552 
canonical chromosomes were removed from subsequent analysis. 553 
 554 
Genomic region enrichment 555 
To determine the preference of co-localised NIPBL and BRD4 binding to specific chromatin 556 
states we performed fisher enrichment analysis on a chromatin state map in mouse 557 
embryonic stem cells (ChromHMM, mm9). This state map has annotated the genome into six 558 
major chromatin states including; active promoter, poised promoter, strong enhancer, poised 559 
or weak enhancer, insulator, repressed, transcribed and heterochromatin. 560 
In addition we looked at enrichment of co-localised NIPBL and BRD4 binding sites with Super 561 
Enhancers (SE) regions found in mESC line E14 using data from SEA: Super-Enhancer 562 
Archive35.  563 
We used the consensus set of SE regions from two mES E14 replicates to define SE regions. 564 
 565 
Genomic region enrichment statistics 566 
To calculate enrichment of peaks we used bedtools (2.26.0) fisher test. The fishers odds ratio 567 
was converted to Log2 scale and plotted using R forest plot package. 568 
 569 
URLs 570 
Database of Genomic Variants; http://dgv.tcag.ca/dgv/app/home 571 
Ion AmpliSeq Designer tool; http://www.ampliseq.com 572 
Blacklisted regions; https://sites.google.com/site/anshulkundaje/projects/blacklists 573 
ChromHMM, mm9; https://github.com/gireeshkbogu/chromatin_states_chromHMM_mm9 574 
Super Enhancer Archive; http://www.bio-bigdata.com/SEA/ 575 
pheatmap: Pretty Heatmaps (2015) v1.0.8. https://CRAN.R-project.org/package=pheatmap 576 
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